Our subsidiaries
Sosei R&D Ltd.
| Capital | JPY 182,737,452 |
|---|---|
| Scope of business | Licensing and business development outside Japan |
| Representative Director | Peter Bains |
| Holding company stake | 100% |
| Address | 2nd Floor, London BioScience Innovation Centre 2 Royal College Street London NW1 0NH, United Kingdom (map) Tel: +44-(0)20-7691-2081 Fax: +44-(0)20-7209-2484 |
Heptares Therapeutics Ltd.
| Capital | JPY 45,525,238 |
|---|---|
| Scope of business | Drug discovery based on targeting of G protein-coupled receptors |
| Representative Director, CEO | Malcolm Weir, CEO |
| Holding company stake | 100% |
| Address | BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX, UK (map) |
| URL | www.heptares.com |
Jitsubo Co. Ltd.
| Capital | JPY 100,000,000 |
|---|---|
| Scope of business | Development of peptide drugs, licensing of peptide API manufacturing technology |
| Representative Director | Teruaki Tsukamoto（Chief Executive Officer） Kazuaki Kanai（Senior V.P., Research and Development） |
| Holding company stake | 43.7% |
| Address | Life Science Research Center 4-1 1-1-43 Suehiro-cho, Tsurumi, Yokohama 230-0045, Japan |
| URL | www.jitsubo.com/en/ |
Sosei Co. Ltd.
| Capital | JPY 250,000,000 |
|---|---|
| Scope of business | Drug development and sales, business development in Japan |
| Representative Director | Tadayoshi Yasui |
| Holding company stake | 100% (voting rights) |
| Address | PMO Hanzomon 11F 2-1 Kojimachi, Chiyoda-ku Tokyo 102-0083 Japan (map) Tel: +81-(0)3-5210-3290 (general enquiries) Fax: +81-(0)3-5210-3291 |
Sosei CVC Ltd.
| Capital | JPY 10,000,000 |
|---|---|
| Scope of business | Managing Sosei RMF1 (Regenerative Medicine Fund) |
| Representative Director | Peter Bains |
| Holding company stake | 90% |
| Address | PMO Hanzomon 11F 2-1 Kojimachi, Chiyoda-ku Tokyo 102-0083 Japan (map) Tel: +81-(0)3-5210-3290 (general enquiries) Fax: +81-(0)3-5210-3291 |